Venetoclax (Venclexta®) is an oral, first-in-class small molecule that restores apoptosis by binding to and inhibiting the B-cell lymphoma-2 (BCL-2) anti-apoptotic protein. In myeloid malignancies, overexpression of BCL-2 allows leukemic cells to evade programmed cell death, making it a critical therapeutic target.
Clinical Indications and Efficacy
Venetoclax is FDA-approved for the treatment of newly diagnosed Acute Myeloid Leukemia (AML) in adults who are $\ge$ 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy.
- Combination Therapy: It is used in combination with hypomethylating agents (azacitidine or decitabine) or low-dose cytarabine (LDAC).
- Evidence: In the VIALE-A trial, the combination of venetoclax plus azacitidine demonstrated superior median overall survival (14.7 months vs. 9.6 months) and higher complete remission (CR/CRi) rates (66% vs. 28%) compared to azacitidine alone.
High-Yield Pharmacist Considerations for BCOP
- Dosing & Ramp-Up: To mitigate the risk of Tumor Lysis Syndrome (TLS), venetoclax requires a dose ramp-up during the first cycle (typically 100 mg on day 1, 200 mg on day 2, and reaching the target dose by day 3). The target dose is 400 mg daily when used with HMAs and 600 mg daily when used with LDAC.
- Drug-Drug Interactions: Venetoclax is a major CYP3A4 substrate. Concomitant use with strong CYP3A4 inhibitors (e.g., posaconazole, voriconazole) requires a dose reduction of at least 75%. In clinical practice, many clinicians utilize 100 mg daily when used with posaconazole.
- Myelosuppression Management: Responses are faster than with HMAs alone, often seen within 1–2 cycles. Because significant myelosuppression can occur, patients often require a 7–14 day break between 28-day cycles once a clear bone marrow is confirmed at day 21–28.
- TLS Monitoring: While more common in CLL, TLS is a risk in AML; WBC counts should be < 25,000/mcL before starting therapy, sometimes requiring cytoreduction with hydroxyurea.
Synonyms
Venclexta